The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Florbetapir PET analysis of amyloid-β deposition in the presenilin 1 E280A autosomal dominant Alzheimer's disease kindred: a cross-sectional study
Open accessAbstract
Summary Background Fibrillar amyloid-β (Aβ) is thought to begin accumulating in the brain many years before the onset of clinical impairment in patients with Alzheimer’s disease. By assessing the accumulation of Aβ in people at risk of genetic forms of Alzheimer’s disease, we can identify how early preclinical changes start in individuals certain to develop dementia later in life. We sought to characterise the age-related accumulation of Aβ deposition in presenilin 1 (PSEN1) E280A mutation carriers across the spectrum of preclinical disease. Methods Between Aug 1 and Dec 6, 2011, members of the familial Alzheimer’s disease Colombian kindred aged 18–60 years were recruited from the Alzheimer’s Prevention Initiative’s registry at the University of Antioquia, Medellín, Colombia. Cross-sectional assessment using florbetapir PET was done in symptomatic mutation carriers with mild cognitive impairment or mild dementia, asymptomatic carriers, and asymptomatic non-carriers. These assessments were done at the Banner Alzheimer’s Institute in Phoenix, AZ, USA. A cortical grey matter mask consisting of six predefined regions. was used to measure mean cortical florbetapir PET binding. Cortical-to-pontine standard-uptake value ratios were used to characterise the cross-sectional accumulation of fibrillar Aβ deposition in carriers and non-carriers with regression analysis and to estimate the trajectories of fibrillar Aβ deposition. Findings We enrolled a cohort of 11 symptomatic individuals, 19 presymptomatic mutation carriers, and 20 asymptomatic non-carriers, ranging in age from 20 to 56 years. There was greater florbetapir binding in asymptomatic PSEN1 E280A mutation carriers than in age matched non-carriers. Fibrillar Aβ began to accumulate in PSEN 1E280A mutation carriers at a mean age of 28·2 years (95% CI 27·3–33·4), about 16 years and 21 years before the predicted median ages at mild cognitive impairment and dementia onset, respectively. 18F florbetapir binding rose steeply over the next 9·4 years and plateaued at a mean age of 37·6 years (95% CI 35·3–40·2), about 6 and 11 years before the expected respective median ages at mild cognitive impairment and dementia onset. Prominent florbetapir binding was seen in the anterior and posterior cingulate, precuneus, and parietotemporal and frontal grey matter, as well as in the basal ganglia. Binding in the basal ganglia was not seen earlier or more prominently than in other regions. Interpretation These findings contribute to the understanding of preclinical familial Alzheimer’s disease and help set the stage for assessment of amyloid-modifying treatments in the prevention of familial Alzheimer’s disease. Funding Avid Radiopharmaceuticals, Banner Alzheimer’s Foundation, Nomis Foundation, Anonymous Foundation, Forget Me Not Initiative, Colciencias, National Institute on Aging, and the State of Arizona.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
McKhann, G. M., Knopman, D. S., Chertkow, H., Hyman, B. T., Jack, C. R., Kawas, C. H., Klunk, W. E., Koroshetz, W. J., Manly, J. J., Mayeux, R., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.005 · Cited by 18,657
Albert, M. S., DeKosky, S. T., Dickson, D., Dubois, B., Feldman, H. H., Fox, N. C., Gamst, A., Holtzman, D. M., Jagust, W. J., Petersen, R. C., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.008 · Cited by 10,152
Sheikh (1986) · doi:10.1300/j018v05n01_09 · Cited by 7,236
Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade
Jack, C. R., Knopman, D. S., Jagust, W. J., Shaw, L. M., Aisen, P. S., Weiner, M. W., Petersen, R. C., & Trojanowski, J. Q. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70299-6 · Cited by 4,806
Clinical and biomarker changes in dominantly inherited Alzheimer's disease
Bateman, R. J., Xiong, C., Benzinger, T. L. S., Fagan, A. M., Goate, A., Fox, N. C., Marcus, D. S., Cairns, N. J., Xie, X., Blazey, T. M., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1202753 · Cited by 3,814
Association of apolipoprotein E allele ϵ4 with late‐onset familial and sporadic Alzheimer's disease
Saunders, A. M., Strittmatter, W. J., Schmechel, D., St. George-Hyslop, P. H., Pericak-Vance, M. A., Joo, S. H., Rosi, B. L., Gusella, J. F., Crapper-MacLachlan, D. R., Alberts, M. J., et al. (1993) · Neurology · doi:10.1212/wnl.43.8.1467 · Cited by 3,786
Phases of Aβ-deposition in the human brain and its relevance for the development of AD
Thal, D. R., Rüb, U., Orantes, M., & Braak, H. (2002) · Neurology · doi:10.1212/wnl.58.12.1791 · Cited by 3,490
Reiman, E. M., Caselli, R. J., Yun, L. S., Chen, K., Bandy, D., Minoshima, S., Thibodeau, S. N., & Osborne, D. (1996) · New England Journal of Medicine · doi:10.1056/nejm199603213341202 · Cited by 1,366
Self-citationAmyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging
Rowe, C. C., Ellis, K. A., Rimajova, M., Bourgeat, P., Pike, K. E., Jones, G., Fripp, J., Tochon-Danguy, H., Morandeau, L., O'Keefe, G., et al. (2010) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.04.007 · Cited by 986
Staging of Alzheimer-Related Cortical Destruction
Braak, H., Braak, E., & Bohl, J. (2008) · European Neurology · doi:10.1159/000116984 · Cited by 836
Research works printed but not linked: 24
- Fleisher, 2011, Using positron emission tomography and florbetapir F18 to image cortical amyloid in patients with mild cognitive impairment or dementia due to Alzheimer disease, Arch Neurol, 68, 1404, 10.1001/archneurol.2011.150 · DOI · Paper page
- Duque-Castano, 1999, [Neuropathological findings in early-onset Alzheimer's disease (E280a-PS1 mutation)], Rev Neurol, 29, 1
- Reiman, 2010, Alzheimer's prevention initiative: a proposal to evaluate presymptomatic treatments as quickly as possible, Biomark Med, 4, 3, 10.2217/bmm.09.91 · DOI
- Fleisher, 2005, Identification of Alzheimer disease risk by functional magnetic resonance imaging, Arch Neurol, 62, 1881, 10.1001/archneur.62.12.1881 · DOI
- Klunk, 2007, Amyloid deposition begins in the striatum of presenilin-1 mutation carriers from two unrelated pedigrees, J Neurosci, 27, 6174, 10.1523/JNEUROSCI.0730-07.2007 · DOI · Paper page
- Scholl, 2011, Glucose metabolism and PIB binding in carriers of a His163Tyr presenilin 1 mutation, Neurobiol Aging, 32, 1388, 10.1016/j.neurobiolaging.2009.08.016 · DOI
- Tanzi, 2005, Twenty years of the Alzheimer's disease amyloid hypothesis: a genetic perspective, Cell, 120, 545, 10.1016/j.cell.2005.02.008 · DOI · Paper page
- Reisberg, 1988, Functional assessment staging (FAST), Psychopharmacol Bull, 24, 653
- Clark, 2011, Use of florbetapir-PET for imaging beta-amyloid pathology, JAMA, 305, 275, 10.1001/jama.2010.2008 · DOI · Paper page
- Fleisher, 2012, APOE4 and age effects on florbetapir PET in healthy aging and Alzheimer disease, Neurobiol Aging
- Villain, 2012, Regional dynamics of amyloid-beta deposition in healthy elderly, mild cognitive impairment and Alzheimer's disease: a voxelwise PiB-PET longitudinal study, Brain, 135, 2126, 10.1093/brain/aws125 · DOI · Paper page
- Edison, 2012, Can target-to-pons ratio be used as a reliable method for the analysis of [11C]PiB brain scans?, Neuroimage, 60, 1716, 10.1016/j.neuroimage.2012.01.099 · DOI
- Villemagne, 2009, High striatal amyloid beta-peptide deposition across different autosomal Alzheimer disease mutation types, Arch Neurol, 66, 1537, 10.1001/archneurol.2009.285 · DOI · Paper page
- Sojkova, 2011, Longitudinal patterns of beta-amyloid deposition in nondemented older adults, Arch Neurol, 68, 644, 10.1001/archneurol.2011.77 · DOI
- Meltzer, 2000, Does cerebral blood flow decline in healthy aging? A PET study with partial-volume correction, J Nucl Med, 41, 1842
- Tohka, 2004, Fast and robust parameter estimation for statistical partial volume models in brain MRI, Neuroimage, 23, 84, 10.1016/j.neuroimage.2004.05.007 · DOI · Paper page
- Koivunen, 2008, PET amyloid ligand [11C]PIB uptake shows predominantly striatal increase in variant Alzheimer's disease, Brain, 131, 1845, 10.1093/brain/awn107 · DOI
- Remes, 2008, Carbon 11-labeled pittsburgh compound B positron emission tomographic amyloid imaging in patients with APP locus duplication, Arch Neurol, 65, 540, 10.1001/archneur.65.4.540 · DOI
- Braak, 1990, Alzheimer's disease: striatal amyloid deposits and neurofibrillary changes, J Neuropathol Exp Neurol, 49, 215, 10.1097/00005072-199005000-00003 · DOI · Paper page
- Suenaga, 1990, Modified Bielschowsky stain and immunohistochemical studies on striatal plaques in Alzheimer's disease, Acta Neuropathol, 80, 280, 10.1007/BF00294646 · DOI
- Brilliant, 1997, The distribution of amyloid beta protein deposition in the corpus striatum of patients with Alzheimer's disease, Neuropathol Appl Neurobiol, 23, 322, 10.1111/j.1365-2990.1997.tb01302.x · DOI
- Klunk, 2004, Imaging brain amyloid in Alzheimer's disease with Pittsburgh compound-B, Ann Neurol, 55, 306, 10.1002/ana.20009 · DOI · Paper page
- Price, 2005, Kinetic modeling of amyloid binding in humans using PET imaging and Pittsburgh compound-B, J Cereb Blood Flow Metab, 25, 1528, 10.1038/sj.jcbfm.9600146 · DOI · Paper page
- Choi, 2009, Preclinical properties of 48F-AV-45: a PET agent for Abeta plaques in the brain, J Nucl Med, 50, 1887, 10.2967/jnumed.109.065284 · DOI · Paper page
Cited by
Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria
Dubois, B., Feldman, H. H., Jacova, C., Hampel, H., Molinuevo, J. L., Blennow, K., DeKosky, S. T., Gauthier, S., Selkoe, D., Bateman, R., et al. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70090-0 · Cited by 3,321
Microglia in Alzheimer’s disease
Hansen, D. V., Hanson, J. E., & Sheng, M. (2018) · Journal of Cell Biology · doi:10.1083/jcb.201709069 · Cited by 1,935
The Amyloid-β Pathway in Alzheimer’s Disease
Hampel, H., Hardy, J., Blennow, K., Chen, C., Perry, G., Kim, S. H., Villemagne, V. L., Aisen, P., Vendruscolo, M., Iwatsubo, T., et al. (2021) · Molecular Psychiatry · doi:10.1038/s41380-021-01249-0 · Cited by 1,952
Tau pathology and neurodegeneration
Spillantini, M. G., & Goedert, M. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70090-5 · Cited by 1,133
Biomarker Modeling of Alzheimer’s Disease
Jack, C. R., & Holtzman, D. M. (2013) · Neuron · doi:10.1016/j.neuron.2013.12.003 · Cited by 1,002
Metadata
- Authors
- Fleisher, A. S., Chen, K., Quiroz, Y. T., Jakimovich, L. J., Gomez, M. G., Langois, C. M., Langbaum, J. B., Ayutyanont, N., Roontiva, A., Thiyyagura, P., Lee, W., Mo, H., Lopez, L., Moreno, S., Acosta-Baena, N., Giraldo, M., Garcia, G., Reiman, R. A., Huentelman, M. J., Kosik, K. S., Tariot, P. N., Lopera, F., & Reiman, E. M.
- Venue
- The Lancet Neurology
- Publisher
- Elsevier BV
- Published
- 2012-12
- Volume
- 11
- Issue
- 12
- Pages
- 1057-1065
- ISSN
- 1474-4422 (ISSN-L)
- OpenAlex
- W2096695700
- Cited by
- 242
- References
- 17
- FWCI
- 19.06
- Type
- journal article
- Language
- en
- Open access
- green
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- Funders
- NOMIS Stiftung
- National Institute on Aging (P30 AG19610, R01 AG031581)
- Arizona State University
- Departamento Administrativo de Ciencia, Tecnología e Innovación (1115-408-20512, 1115-408-20543P30)
- Banner Alzheimer’s Foundation
- Avid Radiopharmaceuticals
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Florbetapir PET analysis of amyloid-β deposition in the presenilin 1 E280A autosomal dominant Alzheimer's disease kindred: a cross-sectional study. https://app.cochat.ai/papers/10.1016/s1474-4422(12)70227-2
- The paper
- Fleisher, A. S., Chen, K., Quiroz, Y. T., Jakimovich, L. J., Gomez, M. G., Langois, C. M., Langbaum, J. B., Ayutyanont, N., Roontiva, A., Thiyyagura, P., Lee, W., Mo, H., Lopez, L., Moreno, S., Acosta-Baena, N., Giraldo, M., Garcia, G., Reiman, R. A., Huentelman, M. J., . . . Reiman, E. M. (2012). Florbetapir PET analysis of amyloid-β deposition in the presenilin 1 E280A autosomal dominant Alzheimer's disease kindred: a cross-sectional study. The Lancet Neurology. https://doi.org/10.1016/s1474-4422(12)70227-2
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.